Sanofi (France)

While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.

This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.

Biopharma companies from across the globe provide updates on their pipelines and business practices.

The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.

Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

This approval marks the first time in a decade Sanofi has had a wholly-owned cancer drug approved.

The active component of the drug, sodium valproate, has been on the market for epilepsy and bipolar disorder since 1967.

It was another busy week for clinical trial updates. Here’s a look.